Hepatitis C virus (HCV) infects more than 185 million individuals worldwide, 20% of chronically infected (HCV+) patients progress to cirrhosis, and 74% show extrahepatic manifestations. Advances in understanding HCV chronic infection and the associated inflammatory processes (involving a complex network of cytokines and chemokines) have led to substantial advancements in the therapy. Combination therapy (PEGylated-interferon-alpha and ribavirin), used in HCV+ patients for more than a decade, shows limited effectiveness and severe adverse effects. Recently, direct antiviral agents (protease or polymerase inhibitors, or NS5A inhibitors) have been used, resulting in better efficacy and tolerance, and a shorter treatment duration. Polymorphisms in the region of the interleukin-28B gene, and circulating CXCL10 levels, are associated with the clearance of HCV after PEGylated-interferonalpha treatment, with/without direct antiviral agents. Understanding the host and viral factors associated with viral clearance is necessary for individualizing therapy, to increase the overall benefits with respect to its costs.
